{
    "nct_id": "NCT06338657",
    "official_title": "A Window of Opportunity Study of Taxanes in Head and Neck Cancer",
    "inclusion_criteria": "* Patients must have histopathologically / cytologically confirmed diagnosis of head and neck squamous cell carcinoma\n* Sites of primary tumor allowed include the oral cavity and oropharynx only. Patients with recurrent disease that is amenable to surgery are eligible\n* Patients may have any stage cancer amenable to surgical resection\n* Patients must be able to provide an archival tissue specimen. Excisional biopsy or core needle biopsy specimens are allowed. Fine needle aspiration samples are not acceptable\n* Patients with oropharynx cancer must have p16 negative disease\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Leukocytes ≥ 3,000/mcL\n* Absolute neutrophil count ≥ 1,500/mcL\n* Platelets ≥ 100,000/mcl\n* Hemoglobin ≥ 9 g/dl\n* Total bilirubin ≤ 1.5 X institutional upper limit of normal\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 X institutional upper limit of normal\n* Creatinine ≤ 1.5 X institutional upper limit of normal\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n  * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy; or\n    * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\n* Ability to understand and the willingness to sign a written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with primary sites of the nasopharynx, salivary gland, or skin\n* Patients that have been previously treated with taxane chemotherapies\n* Patients that have previously received radiation to the site of planned surgery\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to FID-007 or other agents used in study\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants\n* Any diagnosis of immunodeficiency or patients receiving immunosuppressive therapy within 14 days of enrollment. Prednisone dose of ≤ 10mg is allowed",
    "miscellaneous_criteria": ""
}